Aventis/VaxGen AIDS Vaccine Phase III Update Will Be Heard By Advisory Committee Sept. 23

FDA's Vaccines & Related Biologics Advisory Committee will discuss ongoing study of Aventis' ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX. The committee will review Aventis' meningococcal conjugate vaccine Menactra Sept. 22.